Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-9190 and GS-9256 response-guided combination therapy in treatment-naive genotype 1 chronic hepatitis C
2010-020911-35Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Sep 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tegobuvir, GS-9256, ribavirin and peginterferon alfa-2a in chronic hepatitis C (CHC) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Sustained virologic response. Started Sep 2010; status: terminated.
02
Drugs
tegobuvirGS-9256ribavirinpeginterferon alfa-2a
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2010-020911-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020911-35.